PHILADELPHIA, October 26, 2021 (Newswire.com) – Senzo, a leading pre-commercial stage diagnostics company, is pleased to announce the confirmation of Jeremy Stackawitz as CEO. Stackawitz joins Senzo from listed diagnostics company Quotient Limited where he served as President for over 10 years. Stackawitz will oversee the commercialization of Senzo’s recent diagnostic technological breakthroughs as well as overall management of the business moving forward.
During his time at Quotient, Stackawitz spearheaded its growth and listing on the NASDAQ stock exchange. With a bachelor’s degree from Dartmouth College, an MBA in Healthcare Management from The Wharton School, and roles with McKinsey and Johnson & Johnson, Stackawitz brings extensive healthcare and testing domain experience to Senzo.
“We are extremely fortunate to have Jeremy join the team after five very productive years of crucial R&D work. Jeremy has both a deep understanding of the industry and the real-world operational experience needed to move our innovation from the clinic to the customer at speed, which, in the current environment, is what really matters,” said Aron Rachamim, founder and President of Senzo.
“When Senzo approached me and shared the technologies they are about to bring to market, I knew it was a rare opportunity,” said Stackawitz of his new role. “The technologies Senzo has developed have the potential to not only change the diagnostics industry but also improve patient care worldwide.”
About Senzo: Senzo is a pre-commercial diagnostics company developing innovative testing products. Senzo was founded with the vision of utilizing microfluidics to create mobile devices with the ability to accurately identify diseases at their very inception. Senzo is creating modern systems which are fast, accurate, and mobile. Senzo is bringing testing to the patient instead of sending patient samples offsite to specialist laboratories around the world. With insights generated at the point of care, healthcare professionals can identify life-threatening diseases at an earlier stage, improving treatment outcomes and saving lives.